Tell us what's wrong and we'll take a look.
Thanks – we got it. We'll review and follow up if needed.
A timely investigation into the ethics, history, and potential of human cloning from Professor Ian Wilmut, who shocked scientists, ethicists, and the public in 1997 when his team unveiled Dolly that very special sheep who was cloned from a mammary cell. With award-winning science journalist Roger Highfield, Wilmut explains how Dolly launched a medical revolution in which cloning is now used to make stem cells that promise effective treatments for many major illnesses. Dolly's birth also unleashed an avalanche of speculation about the eventuality of cloning babies, which Wilmut strongly opposes. However, he does believe that scientists should one day be allowed to combine the cloning of human embryos with genetic modification to free families from serious hereditary disease. In effect, he is proposing the creation of genetically altered humans."
Sir Ian Wilmut is an embryologist who famously led the team that successfully cloned 'Dolly the sheep' in the mid-1990s. To achieve this technical feat, the team established a technique for transferring nuclei from adult sheep cells to unfertilized sheep eggs that had had their own nuclei removed. He now conducts research on adult cells, using techniques that avoid the need to obtain embryonic cells. Ian's current work aims to convert skin cells into stem cells that have the ability to form all tissues. By deriving these cells from donors who have inherited degenerative diseases, it is possible to gain new understanding of how diseases arise and search for medicines that are able to prevent the degeneration. In the long run, stem cells will be used in new treatments. Ian is a strong advocate of a proposal to develop a global network of cell banks, making it possible for anyone in the world to have access to such cell therapy.
Readwise Books is an ebook & audiobook platform that automatically logs how much you and your friends read, making it fun and easy to read more. Learn more →
Enter your email to continue. We'll create your account if you're new here.